Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2015
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Metabolic syndrome; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 02 Dec 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrial.gov record.
- 01 Jul 2014 New trial record